Clinical investigation最新文献_第9页

A twice-daily, fixed-dose combination of aclidinium bromide and formoterol fumarate for the treatment of chronic obstructive pulmonary disease 一种每日两次的固定剂量的溴化克立啶和富马酸福莫特罗的组合，用于治疗慢性阻塞性肺疾病

Clinical investigation Pub Date : 2015-09-18 DOI: 10.4155/CLI.15.34

J. Beier

引用次数: 0

David Doherty, co-founder of 3G Doctor David Doherty, 3G医生的联合创始人

Clinical investigation Pub Date : 2015-09-18 DOI: 10.4155/CLI.15.29

Davis Doherty

引用次数: 1

STRATOS 1 and 2: considerations in clinical trial design for a fully human monoclonal antibody in severe asthma STRATOS 1和2:重度哮喘全人源单克隆抗体临床试验设计的考虑

Clinical investigation Pub Date : 2015-09-14 DOI: 10.4155/CLI.15.38

R. Panettieri, C. Brightling, Ulf Sjobring, AnnaMaria Péterffy, G. Tornling, Sami Z. Daoud, K. Ranade, Sally Hollis, G. Colice

引用次数: 17

MESOS: considerations in designing a mechanistic study for a biologic used to treat asthma MESOS:设计用于治疗哮喘的生物制剂的机制研究的考虑

Clinical investigation Pub Date : 2015-09-14 DOI: 10.4155/CLI.15.36

C. Brightling, Millie Wang, M. Braddock, L. Nordenmark, Mattis Gottlow, G. Colice

引用次数: 6

TROPOS: designing a clinical trial to evaluate the oral corticosteroid-sparing effect of a biologic in severe asthma 目的:设计一项临床试验，评估一种生物制剂在严重哮喘中的口服皮质类固醇节约作用

Clinical investigation Pub Date : 2015-09-14 DOI: 10.4155/CLI.15.37

W. Busse, Millie Wang, J. Gibson, Mattis Gottlow, M. Braddock, G. Colice

引用次数: 10

Turoctocog alfa in the treatment of individuals with hemophilia A: review of quality of life data collected in Phase III trials Turoctocog alfa治疗A型血友病患者:III期试验收集的生活质量数据回顾

Clinical investigation Pub Date : 2015-09-09 DOI: 10.4155/CLI.15.43

S. Seremetis, R. Kulkarni, A. Regnault, E. Santagostino

引用次数: 1

Data monitoring committees in clinical trials: best practice, complexities and considerations 临床试验中的数据监测委员会:最佳实践、复杂性和考虑因素

Clinical investigation Pub Date : 2015-07-30 DOI: 10.4155/CLI.15.31

S. Day

{"title":"Data monitoring committees in clinical trials: best practice, complexities and considerations","authors":"S. Day","doi":"10.4155/CLI.15.31","DOIUrl":"https://doi.org/10.4155/CLI.15.31","url":null,"abstract":"What is the problem all about? Clinical trials are sometimes described as being rather ‘blunt’ instruments, and that often may be true: we use them to find answers to very broad questions such as ‘does this drug work better than a control drug?’ But they are also very important and delicate instruments: we use them to find answers to questions such as ‘how much does this drug work?’ ‘what is the safety profile of this drug?’ and so on. And in the nature of research, we do not know what the right answer is and we have to rely on the clinical trial to give us the right answer. If anything is broken in the trial, it might give us the wrong answer – but we might have no way of know whether answer is right or wrong (unless we can see a break, or maybe just a dent, in the trial). Bias is one of the big concerns in any trial and it is why we typically use the key building blocks of blinding and randomization. It is also why we typically do not look at the data every week or two and see how one treatment is doing compared with another. We set up an experiment, we allow it to run unhindered, and then we look at the results. The problem (of course) is what should we do if something in the trial is going in a very different direction to where we thought it was? This might be that the new treatment is far better than the control treatment – even to the extent that it is far better than we initially expected. Patients are potentially being disadvantaged by being randomized to the control arm; something needs to be done. Or it might be that our new treatment, while backed by some of the greatest investors and optimists the world has produced, actually is not working. We are wasting a lot of time, resource, patients’ goodwill and, not to forget ... quite a lot of money. Something surely needs to be done! So we are in the dilemma of wanting to run a trial, without external interference, maintaining blinding and randomization, but we also want to know what the results look like. Enter the independent data monitoring committee (DMC).","PeriodicalId":10369,"journal":{"name":"Clinical investigation","volume":"15 1","pages":"615-617"},"PeriodicalIF":0.0,"publicationDate":"2015-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86175439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Rechallenge with imatinib in advanced gastrointestinal stromal tumors: clinical implications of the RIGHT trial 伊马替尼治疗晚期胃肠道间质瘤:RIGHT试验的临床意义

Clinical investigation Pub Date : 2015-07-30 DOI: 10.4155/CLI.15.26

C. Yoo, Yoon-Koo Kang

引用次数: 1

Nursing to regulator, rowing to digital health 护理转向监管，划船转向数字医疗

Clinical investigation Pub Date : 2015-07-30 DOI: 10.4155/cli.15.28

E. Davies

引用次数: 0

Ruxolitinib for patients with polycythemia vera who have had an inadequate response or are intolerant to hydroxyurea: a critical appraisal Ruxolitinib对真性红细胞增多症反应不足或对羟基脲不耐受的患者:一项关键评价

Clinical investigation Pub Date : 2015-07-30 DOI: 10.4155/CLI.15.33

G. Barosi

引用次数: 0